PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Vaccine approval process • Vaccines price list PART 06: Pipeline portfolio PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by type of human vaccine • Live attenuated vaccine • Killed vaccine • Toxoid vaccine • Genetically modified/engineered vaccine • Synthetic vaccines • Dendritic cells vaccines • Conjugate vaccines • Subunit vaccines PART 09: Market segmentation by composition • Mono vaccine • Combination vaccines PART 10: Market segmentation by route of administration • Oral vaccines • Intramuscular vaccines • Intranasal vaccines • Intradermal vaccines PART 11: Market segmentation by type of human vaccine PART 12: Global therapeutic human vaccines market • Market overview • Market size and forecast PART 13: Global preventable human vaccines market • Market overview • Market size and forecast PART 14: Global pediatric preventable human vaccines market • Market size and forecast PART 15: Global adult preventable human vaccines market • Market size and forecast PART 16: Geographical segmentation • Human vaccines market in the Americas • Market size and forecast • Human vaccines market in EMEA • Market size and forecast • Human vaccines market in APAC • Market size and forecast PART 17: Market drivers • Growing awareness about vaccination and immunization programs • Inclusion in national immunization schedule • High demand for pediatric vaccines • Increase in prevalence of infectious diseases PART 18: Impact of drivers PART 19: Market challenges • Inadequate vaccination coverage • Vaccine storage and handling issues • High risk associated with vaccine development • Stringent regulatory process • Misperception about vaccines • Adverse side effects of vaccines PART 20: Impact of drivers and challenges PART 21: Market trends • Increase in strategic alliance and M&A • Entry of novel vaccines • Increase in investment • Focus on emerging markets • Emergence of resistant strains • Public-private initiatives PART 22: Vendor landscape • Competitive scenario PART 23: Key vendor analysis • GSK • Sanofi • Merck • Pfizer • Other prominent vendors PART 24: Appendix • List of abbreviations PART 25: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Requirements for BLA submission in the US Exhibit 03: Developmental steps required to reach the vaccine licensing stage Exhibit 04: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion Exhibit 05: Regulatory testing of licensed vaccines Exhibit 06: Pediatric/VFC vaccine price list Exhibit 07: Pediatric influenza vaccine price list Exhibit 08: Adult vaccine price list Exhibit 09: Adult influenza vaccine price list Exhibit 10: GlaxoSmithKline: Vaccine pipeline Exhibit 11: Novartis: Vaccine pipeline Exhibit 12: Merck: vaccine pipeline Exhibit 13: Pfizer: vaccine pipeline Exhibit 14: Sanofi: vaccine pipeline Exhibit 15: TuBerculosis Vaccine Initiative (TBVI): vaccine pipeline Exhibit 16: Some pipeline compounds under development in 2015 Exhibit 17: Top 10 pharmaceutical companies based on global vaccine revenues in 2014 ($ millions) Exhibit 18: Global human vaccines market 2015-2020 ($ billions) Exhibit 19: SWOT analysis Exhibit 20: Five forces analysis Exhibit 21: Global human vaccines market segmentation by type of vaccine Exhibit 22: Examples of vaccines by type Exhibit 23: Global human vaccines market segmentation by composition Exhibit 24: Global human vaccines market segmentation by route of administration Exhibit 25: Route of administration for different vaccines Exhibit 26: Global human vaccines market types Exhibit 27: Global preventable and therapeutic human vaccines market share 2015 Exhibit 28: Global therapeutic human vaccines market 2015-2020 ($ billions) Exhibit 29: Global preventable human vaccines market 2015-2020 ($ billions) Exhibit 30: Global preventable human vaccines market categories Exhibit 31: Global pediatric and adult preventable human vaccines market share 2015 Exhibit 32: Global pediatric preventable human vaccines market segmentation 2015 Exhibit 33: Global pediatric preventable human vaccines market 2015-2020 ($ billions) Exhibit 34: Global adult preventable human vaccines market share 2015 Exhibit 35: Global adult preventable human vaccines market 2015-2020 ($ billions) Exhibit 36: Global human vaccines market by geography 2015 Exhibit 37: Global human vaccines market by region 2015-2020 ($ billions) Exhibit 38: Human vaccines market in the Americas 2015-2020 ($ billions) Exhibit 39: Human vaccines market in EMEA 2015-2020 ($ billions) Exhibit 40: Human vaccines market in APAC 2015-2020 ($ billions) Exhibit 41: Impact of drivers Exhibit 42: Global immunization coverage 2014 Exhibit 43: A typical cold chain process Exhibit 44: Adverse effects associated with some preventable human vaccines Exhibit 45: Impact of drivers and challenges Exhibit 46: M&A in the vaccine industry Exhibit 47: Overview of major vaccine-related acquisitions (2005-2012) Exhibit 48: Market share analysis of top pharma vaccine companies, 2014 Exhibit 49: GSK: Business segmentation by revenue 2014 Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 51: GSK: Geographical segmentation by revenue 2014 Exhibit 52: GSK: YoY revenue growth of Infanrix/Pediarix 2012-2014 ($ millions) Exhibit 53: GSK: YoY revenue growth of Hepatitis vaccine 2012-2014 ($ millions) Exhibit 54: GSK: YoY revenue growth of Synflorix 2012-2014 ($ millions) Exhibit 55: GSK: YoY revenue growth of Rotarix 2012-2014 ($ millions) Exhibit 56: GSK: YoY revenue growth of Boostrix 2012-2014 ($ millions) Exhibit 57: GSK: Meningitis vaccine revenue 2013 and 2014 ($ millions) Exhibit 58: GSK: Travel and paediatrics vaccine revenue 2013 and 2014 ($ millions) Exhibit 59: Key takeaways Exhibit 60: Sanofi: Business segmentation by revenue 2014 Exhibit 61: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 62: Sanofi: Geographical segmentation by revenue 2014 Exhibit 63: Sanofi: YoY revenue growth of Polio/pertussis/Hib vaccines ($ millions) Exhibit 64: Sanofi: YoY revenue growth of influenza vaccines 2012-2014 ($ millions) Exhibit 65: Sanofi: YoY revenue growth of meningitis/pneumonia vaccine 2012-2014 ($ millions) Exhibit 66: Sanofi: YoY revenue growth of adult booster vaccine 2012-2014 ($ millions) Exhibit 67: Sanofi: YoY revenue growth of travel and other endemic vaccines 2012-2014 ($ millions) Exhibit 68: Key takeaways Exhibit 69: Merck: Business segmentation by revenue 2014 Exhibit 70: Merck: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 71: Merck: Geographical segmentation by revenue 2014 Exhibit 72: Merck: YoY revenue growth of Gardasil 2012-2014 ($ millions) Exhibit 73: Merck: YoY revenue growth of ProQuad/MMR II/Varivax 2012-2014 ($ millions) Exhibit 74: Merck: YoY revenue growth of Zostavax 2012-2014 ($ millions) Exhibit 75: Merck: YoY revenue growth of Pneumovax 23 2012-2014 ($ millions) Exhibit 76: Merck: YoY revenue growth of RotaTeq 2012-2014 ($ millions) Exhibit 77: Key takeaways Exhibit 78: Pfizer: Business segmentation by revenue 2014 0 Exhibit 79: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions) 1 Exhibit 80: Pfizer: Geographical segmentation by revenue 2014 2 Exhibit 81: Pfizer: YoY revenue growth of Prevnar family 2012-2014 ($ millions) 3 Exhibit 82: Key takeaways

GlaxoSmithKline, Merck, Pfizer, Sanofi, Abbott, AstraZeneca, Bavarian Nordic, Baxter, Bharat Biotech, Bharat Immunologicals and Biologicals , bioCSL, Bio Med, Crucell, Dynavax Technologies, Indian Immunologicals, Janssen Pharmaceuticals, Kaketsuken, LG Life Sciences, Mitsubishi Tanabe Pharma, Lupin, Nuron, Novartis, Protein Sciences Corporation, Panacea Biotec, Roche, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, S K Chemicals, Takeda Pharmaceutical, Valeant Pharmaceuticals, Zydus Cadila.